Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP 

  • The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate-to-severe asthma regardless of biomarker status  
  • The DUET phase 2a study met its primary and key secondary endpoints in chronic rhinosinusitis with nasal polyps, reinforcing lunsekimig's potential as a respiratory treatment
  • The exploratory VELVET phase 2b study did not meet its primary endpoint in moderate-to-severe atopic dermatitis
  • In all studies, lunsekimig was well tolerated